<?xml version="1.0" encoding="iso-8859-1"?><rss version="2.0">
<channel>
<title>Novartis International AG</title>
<link>http://www.novartis.com</link>
<item>
<title>Novartis announces USD 5 billion bond issue</title>
<pubDate>2010-03-10T07:15:00 CET</pubDate>
<link>http://www.novartis.com/newsroom/media-releases/en/2010/1392318.shtml</link>
<description><![CDATA[]]></description>
</item>
<item>
<title>Shareholders approve all proposed resolutions of Novartis Board of Directors</title>
<pubDate>2010-02-26T17:30:00 CET</pubDate>
<link>http://www.novartis.com/newsroom/media-releases/en/2010/1389239.shtml</link>
<description><![CDATA[]]></description>
</item>
<item>
<title>Novartis oral multiple sclerosis development compound GileniaŽ* (FTY720) granted US priority review status</title>
<pubDate>2010-02-22T07:15:00 CET</pubDate>
<link>http://www.novartis.com/newsroom/media-releases/en/2010/1386852.shtml</link>
<description><![CDATA[]]></description>
</item>
<item>
<title>Novartis receives FDA approval of MenveoŽ, a vaccine to prevent meningococcal disease</title>
<pubDate>2010-02-22T07:05:00 CET</pubDate>
<link>http://www.novartis.com/newsroom/media-releases/en/2010/1386845.shtml</link>
<description><![CDATA[]]></description>
</item>
<item>
<title>Novartis drug TasignaŽ receives FDA priority review for newly diagnosed patients with early-stage chronic myeloid leukemia</title>
<pubDate>2010-02-19T07:15:00 CET</pubDate>
<link>http://www.novartis.com/newsroom/media-releases/en/2010/1386313.shtml</link>
<description><![CDATA[]]></description>
</item>
<item>
<title>Novartis gains exclusive rights to Debio 025, an antiviral agent in Phase IIb development as potential first-in-class hepatitis C therapy</title>
<pubDate>2010-02-09T07:15:00 CET</pubDate>
<link>http://www.novartis.com/newsroom/media-releases/en/2010/1381968.shtml</link>
<description><![CDATA[]]></description>
</item>
<item>
<title>Novartis achieves record results in 2009 as momentum from recently launched products drives growth across its entire healthcare portfolio</title>
<pubDate>2010-01-26T07:00:00 CET</pubDate>
<link>http://www.novartis.com/newsroom/media-releases/en/2010/1377026.shtml</link>
<description><![CDATA[]]></description>
</item>
<item>
<title>Novartis oral MS therapy FTY720 shows reduced risk of confirmed disability progression as published in New England Journal of Medicine</title>
<pubDate>2010-01-20T23:05:00 CET</pubDate>
<link>http://www.novartis.com/newsroom/media-releases/en/2010/1375459.shtml</link>
<description><![CDATA[]]></description>
</item>
<item>
<title>Three new Novartis medicines approved in Japan for patients with type 2 diabetes, high blood pressure and advanced kidney cancer</title>
<pubDate>2010-01-20T07:15:00 CET</pubDate>
<link>http://www.novartis.com/newsroom/media-releases/en/2010/1375090.shtml</link>
<description><![CDATA[]]></description>
</item>
<item>
<title>Novartis providing equivalent of over USD 2.5 million in immediate emergency aid for victims of Haiti earthquake</title>
<pubDate>2010-01-18T07:15:00 CET</pubDate>
<link>http://www.novartis.com/newsroom/media-releases/en/2010/1374141.shtml</link>
<description><![CDATA[]]></description>
</item>
</channel>
</rss>
